Type 1 Diabetes TrialNet Clinical Centers - Kansas City
Type 1 Diabetes TrialNet Clinical Centers - Kansas City
批准号:
9270548
负责人:
Mark A. Clements
金额:
$33.58万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-20 至 2019-04-30
关键词:
AdultAreaAutoimmune ProcessBeta CellBiological PreservationBusinessesChicagoChildCitiesClinicClinicalClinical InformaticsClinical TrialsCollaborationsComputerized Medical RecordCost Effectiveness AnalysisDataDevelopmentDiabetes preventionDiagnosisDiseaseDisease ManagementEffectivenessEnrollmentEventExcisionFamilyFutureGoalsHawksHospitalsHourIndividualInformaticsInsulin-Dependent Diabetes MellitusIntakeInterventionKansasLifeLiftingLocationMethodsMidwestern United StatesModelingNotificationOklahomaOutcomeParticipantPathway interactionsPatientsPerformancePersonsPhysiciansPreventionPrevention trialProcessProductivityRadialRecruitment ActivityResearchResearch DesignResearch PersonnelRiskRunningScheduleSiteSpecialistSurveysSystemTechniquesTechnologyTestingTextTherapy Clinical TrialsTimeTravelWichitaclinical research sitecostexperienceflexibilityimprovedinnovationinsulin dependent diabetes mellitus onsetinterestnovelnovel strategiespediatric patientspreventpublic health relevanceresponsescreeningsuccesstooltrial design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Results from the TrialNet Pathway to Prevention (PTP) and the type 1 diabetes (T1D) prevention trials indicate potential for success in decreasing the autoimmune destruction of beta cells in individuals destined to develop T1D. The ultimate goal is preservation of sufficient beta cell mass to prevent overt T1D. To accomplish that long-term goal, there is a critical need to identify enough individuals at risk for T1D and to
remove both time- and travel-related barriers to participation in T1D prevention trials. The specific objective in this application is to create a Clinical Center and Affiliate Network that wil expand the reach of TrialNet to an under-represented region that is within 4-5 hours of Kansas City, MO. In collaboration with other Clinical Centers and Affiliates, we will help improve identification of subjects at risk for T1D at a rate sufficient to fulfill the enrollment requiremets of current and future trials designed to preserve beta cell mass in subjects at risk for development of T1D, and provide easy access to prevention trials for all subjects at risk in our region. We have commitments for new and existing Affiliates that will target about 3370 families of pediatric patients with existing T1D and almost 470 families/yr of pediatric patients with new onset T1D within a 3 hr radius of Kansas City. In that same region, we have commitments for new Affiliates that will target about 4300 families of adults with existing T1D and 440 families/yr
of adults with new onset T1D. To improve the effectiveness of screening and retention, we will deploy a comprehensive business model that has been previously validated to maximize the performance of clinical trials for therapies in other disease states and will apply a novel real-tie informatics-driven system ("StudyHawk") to identify qualified candidates for participation in PTP. To improve the efficiency of screening, we will leverage real-time event processing ("StudyHawk") to maximize recruitment per hour spent recruiting and will apply Quality Improvement methods to identify and respond to poor performing sites. The ultimate outcome of a Clinical Center in Kansas City will be expanded access to TrialNet and prevention trials in an underserved region, a Midwest network of Clinical Centers, and increased identification of subjects at risk, increased participation in clinical trials, through development of new approaches to increase productivity that will be shared with all of TrialNet.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Type 1 Diabetes TrialNet Clinical Centers - Kansas City
-
批准号:9113649
-
项目类别:
-
资助金额:$42.42万
-
财政年份:2015
-
负责人:Mark A. Clements
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: